What's new — Lung adenocarcinoma¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 1 |
| last 3 months | 1 |
| last 6 months | 3 |
| last year | 9 |
| older than a year | 259 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-08-01 | Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3 — J Clin Oncol ([PMID 42607282](https://pubmed.ncbi.nlm.nih.gov/42607282/){target="_blank" rel="noopener"}) | guidelines |
| 2026-05-02 | Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1 — J Clin Oncol ([PMID 42190143](https://pubmed.ncbi.nlm.nih.gov/42190143/){target="_blank" rel="noopener"}) | guidelines |
| 2026-05-02 | Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 — J Clin Oncol ([PMID 42190141](https://pubmed.ncbi.nlm.nih.gov/42190141/){target="_blank" rel="noopener"}) | guidelines |
| 2026-02-02 | ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol — BMJ Open ([PMID 41628935](https://pubmed.ncbi.nlm.nih.gov/41628935/){target="_blank" rel="noopener"}) | biomarkers |
| 2025-12-01 | Risk-Adapted Lung Cancer Screening Starting Ages for Former Smokers — JAMA Netw Open ([PMID 41632141](https://pubmed.ncbi.nlm.nih.gov/41632141/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2025-12-01 | Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma — Nature ([PMID 41372401](https://pubmed.ncbi.nlm.nih.gov/41372401/){target="_blank" rel="noopener"}) | molecular-landscape |
| 2025-12-01 | Common Determinants of Lung Cancer Screening Uptake in Three High-Risk and Underserved Communities — J Am Coll Radiol ([PMID 41338709](https://pubmed.ncbi.nlm.nih.gov/41338709/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2025-11-01 | Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study — Lancet Oncol ([PMID 41232542](https://pubmed.ncbi.nlm.nih.gov/41232542/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2025-10-07 | A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma — Nat Cancer ([PMID 41057692](https://pubmed.ncbi.nlm.nih.gov/41057692/){target="_blank" rel="noopener"}) | molecular-landscape |
Trials — what has moved¶
42 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 3 |
| trial records updated in the last month | 7 |
| trial records updated in the last 2 months | 10 |
| trial records updated in the last 3 months | 13 |
| trial records updated in the last 6 months | 22 |
| trial records updated in the last year | 31 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-04-16 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Soli | PHASE1, PHASE2 | 857 | Phase 1: Maximum Tolerated Dose (MTD) | 945 | 1714 | 350 |
| 2026-02-02 | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intr | PHASE3 | 418 | For All Regions Other Than the European Union (EU) and Others Acceptin | 123 | 408 | 104 |
| 2024-12-04 | A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzu | PHASE2 | 72 | ICR-assessed ORR (Objective Response Rate) | 41 | 72 | 41 |
| 2024-05-29 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, | PHASE3 | 308 | Progression-Free Survival (PFS) According to Response Evaluation Crite | 104 | 300 | 70 |
| 2024-03-20 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (w | PHASE2 | 373 | Overall Response Rate (ORR) by Blinded Independent Review Committee (B | 487 | 874 | 707 |
40 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| guidelines | 2026-08-01 | 3 | 35 |
| biomarkers | 2026-02-02 | 1 | 28 |
| molecular-landscape | 2025-12-01 | 2 | 25 |
| screening-and-early-detection | 2025-12-01 | 3 | 29 |
| clinical-trials-landscape | 2025-08-09 | 0 | 25 |
| kras-braf-met-her2 | 2025-08-09 | 0 | 26 |
| epidemiology-and-risk-factors | 2025-08-01 | 0 | 25 |
| overview | 2025-07-02 | 0 | 30 |
| histology-and-classification | 2025-06-01 | 0 | 28 |
| immunotherapy | 2025-03-01 | 0 | 26 |
| staging | 2024-12-01 | 0 | 25 |
| alk-ros1-and-fusion-drivers | 2024-08-15 | 0 | 25 |
| egfr-disease | 2024-06-02 | 0 | 25 |
| red-flags-and-safety-concerns | 2024-06-02 | 0 | 25 |
| systemic-therapy | 2024-06-02 | 0 | 30 |
| early-stage-and-perioperative-therapy | 2024-06-01 | 0 | 25 |
| patient-experience-and-advocacy | 2024-05-02 | 0 | 27 |
| molecular-testing | 2024-05-01 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.